Vigorous-intensity plus liraglutide maintains long-term weight loss
Researchers at University of Copenhagen and Hvidovre Hospital who examined four different types of treatment following a diet-induced weight loss, have reported that it is possible for people with obesity to maintain long-term weight loss. In a randomised clinical trial, they combined moderate to vigorous-intensive exercise with appetite-inhibiting obesity medication, an analogue to the appetite-inhibiting hormone GLP-1, and found it was a highly effective treatment after a diet-induced weight loss.
"This is new knowledge for doctors, dietitians and physical therapists to use in practice. This is evidence that we have been missing," explained Professor Signe Torekov at the Department of Biomedical Sciences, who led the study. "The problem is that people are fighting against strong biological forces when losing weight. The appetite increases simultaneously with decreased energy consumption, and this counteracts weight loss maintenance. We have an appetite-stimulating hormone, which increases dramatically when we lose weight, and simultaneously the level of appetite-suppressing hormones drops dramatically. In addition, a weight loss can provoke loss of muscle mass, while the body reduces the energy consumption. Thus, when the focus in obesity treatment has been on how to obtain a weight loss, rather than how to maintain a weight loss—it is really difficult to do something about your situation.
In the study, 215 patients with obesity and low fitness ratings participated in the study. The participants initially followed a low-calorie diet over eight weeks, where they each lost approximately 13 kg, which brought significant improvements to their health with a drop in blood sugar level and blood pressure.
After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomisation to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed.
All participants in the study were weighed monthly and received nutritional and diet counselling with the focus on healthy weight loss according to the guidelines from the Danish health and food administrations.
After one year, the group with exercise alone and the group with obesity medication alone maintained the weight loss of 13 kg and health improvements. The placebo group gained half of the weight back with deterioration of all risk factors, for example for development of Type 2 diabetes and cardiovascular disease.
The most dramatic improvements occurred in the combination group, which followed the exercise program and received obesity medication. The researchers observed additional weight loss in this group, and the total weight loss was approximately 16 kg over one year. The health benefits were also double that of each of the single treatments, ie, twice the loss of fat mass while preserving muscle mass, higher fitness ratings, reduced blood sugar and improved quality of life.
The two groups that exercised increased their fitness rating, lost fat mass and gained muscle mass. This could indicate a healthier weight loss than for people, who had only lost fat mass without increasing the fitness rating.
"It is an important aspect to highlight, as you do not necessarily get a healthier body from losing weight if, at the same time, you lose a lot of muscle mass," added Signe Torekov. "It is great news for public health that a significant weight loss can be maintained with exercise for approximately 115 minute per week performed mostly at vigorous-intensity, such as cycling. And that by combining exercise with obesity medication, the effect is twice as good as each of the individual treatments."
With the study, the researchers now hope people with obesity, together with their care provider, can create a useful framework for maintaining the weight loss.
Signe Torekov noted out that many people with obesity have tried to lose weight before, only to regain the weight. This happens because the general advice is to eat healthier and exercise more.
"Without a follow-up on whether people actually have support to perform exercise, the treatment will not be enough. Therefore, we also followed up with the participants on an ongoing basis to ensure that they received the support they needed in order to exercise. That is necessary, because maintaining weight loss is extremely hard. People need to understand this. Once you have lost weight, you are not "cured." "The ongoing exercise and effort will likely need to continue for many years.”
According to Signe Torekov, this underscores the importance of participating in a mutual weight maintenance program based on feedback when starting a weight loss programme
"Our study also demonstrates that without a structured treatment plan, there is a high risk of gaining the weight back. There were 12 individual consultations over the course of a year, including weighing and diet advice from Danish authorities according to guidelines for healthy weight maintenance. This was just not enough for the placebo group without exercise program, in this group all health benefits gained by weight loss during the eight-week programme were gone after one year, despite frequent weighing and diet and nutritional counselling based on official guidelines. Therefore, it is important that there is a system for supporting people with obesity in maintaining the lifestyle change. Our study can help with this, because we can say this actually works to doctors, dietitians and municipalities, if they create a structured, joint treatment plan with the individual using ongoing follow-ups.”
The study was partly funded by the Novo Nordisk Foundation.